Brutalist Biotech
Max
3
|
5
|
10
|
20
items per feed.
Cutting-edge Biotech news: Presented the old-fashioned way.
Fierce Biotech
Genentech executes another round of layoffs, with 3 VPs axed
(2h)
AI use is surging across HHS, jumping 148% at the FDA in 2025, Bipartisan Policy Center data finds
(3h)
Novo reports data breach, tells clinical trial patients to 'remain vigilant'
(3h)
Beyond Rigid Platforms: Adaptive Adenoviral Platform De-Risks Development to GMP
(5h)
Roche nabs EU approval on label expansions for companion dx platform
(7h)
Predicta links with Spanish university to offer diagnostic for blood cancers
(8h)
Cardiovascular-focused Kardigan plans to bring in cozy $320M haul from upcoming IPO
(8h)
Caribou boosts case that off-the-shelf CAR-T matches autologous drugs ahead of phase 3
(11h)
Fierce Biotech heading to UK to host event amid London Life Sciences Week
(11h)
Takeda’s TYK2 inhibitor beats Bristol Myers’ Sotyktu in phase 3 psoriasis showdown
(13h)
ADA: Novo’s Lange says ‘jury still out’ on CagriSema amid tough retatrutide comparisons
(1d)
Big Pharma-backed SonoThera sounds off with $125M series B for bubble-based genetic delivery
(1d)
Ethyreal Bio manifests with $101M in pack of biotechs gunning for Amgen’s Tepezza
(1d)
Novartis sticks 2nd deal with molecular glue biotech Orionis, this one worth up to $1.4B
(1d)
Cancer-focused Parabilis’ upsized $670M IPO breaks new for record for biotechs
(1d)
Sanofi halts phase 3 autoimmune trial early over insufficient efficacy as pipeline woes continue
(1d)
‘I’m a lot more optimistic today’: Mike Doustdar tells Fierce about pivotal first year as Novo Nordisk CEO
(1d)
From executive assistant to chief executive: Charles River CEO Birgit Girshick on ‘the next big transition’ in the CRO industry
(2d)
GLP-1s may combat depression by multiplying a mood-boosting gut microbe
(2d)
Cancer biotech Parabilis ups IPO plans to potentially record-setting $637M
(2d)
BioPharma Dive
Summit pulls $500M share sale a day after announcing it
(4h)
Sensorion, citing Regeneron competition, shifts focus to a different hearing loss therapy
(5h)
Novartis RNA drug acquired in $12B Avidity deal notches a trial win
(6h)
Takeda’s $4B TYK2 drug tops Bristol Myers’ Sotyktu in head-to-head test
(9h)
Ethyreal starts up with $101M and takes aim at a pair of immune diseases
(1d)
Sanofi stops immune drug trial in latest research setback
(1d)
Parabilis sets a record with a $670M biotech IPO
(1d)
AstraZeneca’s ‘extensive’ obesity drug push; $125M for ultrasound-aided genetic medicine
(1d)
Merck, Gilead report mixed outcomes in key lung cancer, HIV studies
(2d)
Stealthy startup Treeline plans a reverse merger
(2d)
GSK boosts cancer pipeline with $11B Nuvalent buyout
(2d)
City banks nearly $100M for next-gen RNAi drugs
(3d)
Roche stakes $700M on Nurix’s protein-degrading drug
(3d)
Tango data add to growing momentum for pancreatic cancer drugs
(3d)
Incyte to buy blood disorder drug in possibly $2B deal
(3d)
J&J to acquire Firefly, maker of ‘degrader’ antibody drugs, for up to $1B
(3d)
ADA ‘26: Lilly’s dominance, Pfizer’s ‘foundational’ drug and Roche’s ‘me-too’ option
(3d)
Precision under pressure: Logistic solutions for nuclear medicine scalability
(3d)
Innovation alone is no longer enough in biopharma
(3d)
Study data convince Lundbeck to push new migraine drug forward
(6d)
Endpoints News
Inside Makary’s ouster; Another win for Lilly’s triple-G; and more
(3w)
FDA clears Gilead's hepatitis D drug, four years after prior rejection
(3w)
GOP lawmaker asks Trump administration to curb China biotech deals
(3w)
AstraZeneca wins EU backing for breast cancer drug, splitting with FDA panel
(3w)
How Utah’s AI prescribing experiment is going so far
(3w)
FDA grants Daiichi Sankyo and AstraZeneca’s Datroway a key breast cancer approval
(3w)
Tender offer for Recordati; Sobi's gout drug passes Phase 3 test
(3w)
Why one health AI unicorn is giving away its service for free
(3w)
Novartis says Avidity's science could apply beyond muscular dystrophies
(3w)
Biogen, Denali to drop drug in non-genetic Parkinson’s after mid-stage study flop
(3w)
Ibrance heirs, Gilead's Tubulis data and more at #ASCO26
(3w)
Amgen CFO to follow David Reese into retirement; Josh Smiley is out at Zai Lab
(3w)
#ASCO26: Merck partner Kelun outlines Phase 3 lung cancer success in China study
(3w)
#ASCO26: Key head and neck cancer readouts from J&J, Corbus, Summit, Akero and Bicara
(3w)
#ASCO26: New data released for VEGF bispecifics from BioNTech-BMS, Pfizer-3SBio
(3w)
How a group of biotechs ran a covert campaign to push out the FDA commissioner
(3w)
China’s drugmakers to take the stage at #ASCO26
(3w)
BioMarin to seek further approval of Voxzogo in form of short stature
(3w)
Incyte signs AI deals with Genesis Molecular AI, Edison Scientific
(3w)
BMS eyes new campus in Texas; Novartis looks to evict tenant at Slovenian campus
(3w)
BioSpace
Genentech R&D layoffs hit top exec who’s been with the biotech nearly 30 years
(6h)
Sky-high Parabilis, Kailera IPOs spur optimism—but only for derisked biotechs
(7h)
Takeda’s AI-designed pill bests BMS’ Sotyktu in head-to-head psoriasis trial
(7h)
SonoThera bags $125M series B to advance safer gene therapies
(9h)
Novartis tightens bond with Orionis in up to $1.4B molecular glue deal
(9h)
Portugal, Spain and the new biotech frontier
(12h)
The wait continues: pressure to operate lean among factors behind slow job market
(13h)
May layoffs hit nearly 7,000, with most cuts from Takeda, BioNTech
(13h)
Sanofi cans late-stage study for rare autoimmune disease on underwhelming efficacy
(1d)
Disc’s FDA meeting sets ‘clear path’ for embattled rare blood disease drug
(1d)
Lilly bets up to $1B+ with AlzeCure in search for next Alzheimer’s act
(1d)
ASCO wins from RevMed, Akeso/Summit, more; plus more Lilly and more China; ADA on deck
(1d)
Local trade groups must support life sciences in these difficult times
(1d)
Lilly’s $25B+ M&A spree captures half of pharma’s 2026 capacity
(1d)
New biotech group rises to fuel American rockets in China ‘space race’
(1d)
Hikma outlines plan to invest $267M in Ohio plants, creating 350 jobs
(2d)
Four years and 219 lost companies later, biotech still has a cash problem
(2d)
Merck, Gilead serve ‘sweet and sour’ spread after HIV win, cancer stumble
(2d)
ADA: AstraZeneca hands Structure a win with ‘relatively underwhelming’ GLP-1 pill data
(2d)
GSK pays $10.6B for cancer biotech Nuvalent in industry's second-biggest buy of the year
(2d)
STAT News
An obesity drug deep-dive, and peptides move mainstream
(18m)
RFK Jr. claims his calendar is publicly available. We’ve been trying to get it for a year
(50m)
Drinking during pregnancy rose after 2020, new CDC data suggest
(1h)
AMA and lawmakers push back on AI care denials
(1h)
Nonprofit buys experimental cancer drug to maintain patient access
(2h)
Study highlights influence of socioeconomic status on children’s brain development
(2h)
Abridge inks deals with Nvidia and Lilly
(3h)
A suspicious denial pattern in Medicare Advantage
(5h)
Novartis doubles down on molecular glue strategy
(6h)
We’re reading about employer coverage of obesity drugs, another Sanofi setback, and more
(7h)
‘Synthetic lethality’ could trigger another round of biotech MA
(8h)
Enliven Therapeutics’ leukemia drug shows promise in new study
(8h)
HHS responds coolly to paper on alcohol risk
(8h)
Scientists see promise in NIH proposal to cap number of grants they receive
(12h)
How long Covid’s scientific stalemate made it politically erasable
(12h)
We published in Nature Medicine in 2025 for free. In 2026, it cost us $12,850
(12h)
Private Medicare plans erect barriers to rehab care in pursuit of profit, federal investigators find
(16h)
Diabetes association leader apologizes for expulsion of members, pledges to rebuild trust
(1d)
Your sepsis algorithm shouldn’t require a time machine
(1d)
OB-GYN association, deviating from CDC guidance, issues its own vaccine recommendations
(1d)
BioPharma Trend
Ginkgo Datapoints, Tangible Scientific, and Inductive Bio launch ADME-One, a packaged ADME service for hit identification
(2w)
AI Won't Replace Clinical Programmers. It Will Split Them Into Two Groups.
(1mo)
Novo Nordisk and OpenAI Team Up to Integrate AI from Discovery to Supply Chain
(2mo)
Life Biosciences Gets $80M as Cellular Rejuvenation Enters the Clinic
(2mo)
Jeito Closes €1B Fund, Europe's Largest Independent Biopharma Raise
(2mo)
Anthropic Pays $400M for an AI Biotech With Fewer Than Ten People
(2mo)
Epia Neuro Wants to Decode Brain's Movement Intentions After Stroke
(2mo)
Generare Raises €20M to Explore Uncharacterized Chemical Space from Microbial DNA
(2mo)
Enveda’s AI-Discovered Drug Shows Early Atopic Dermatitis Relief
(2mo)
Lilly Signs $2.75B AI Drug Discovery Deal With Insilico
(2mo)
Meta Open Sources Foundation Model That Predicts Brain Responses to Speech, Video, and Text
(2mo)
Two Ex-GSK AI Leads Go Stealth with a New Oncology Drug Discovery Startup
(2mo)
Tempus and Daiichi Sankyo Partner on AI-Guided Cancer Biomarker Discovery
(2mo)
Bioptimus Launches Multimodal Tissue Atlas Across Three Continents
(2mo)
Merck Signs $20M Deal With Quotient to Find IBD Targets Using Somatic Genomics
(2mo)
insitro and Bristol Myers Squibb Add New AI-Found Targets in ALS Research
(2mo)
Latent Labs Launches AI Agent for Antibody Design From a Single Text Prompt
(2mo)
Earendil Labs Gets $787M to Push AI-Designed Antibodies Toward the Clinic
(2mo)
AI-Guided Brain Implant for Memory Loss Gets FDA Breakthrough Status
(2mo)
Dyno Launches Open-Source Agentic Protein Design Suite at GTC 2026
(2mo)
Drug Channels
The Top 15 Specialty Pharmacies of 2025: PBM-Affiliated Pharmacies Dominate While Health Systems and Independents Gain Ground (rerun)
(10h)
Mapping the Vertical Integration of Insurers, PBMs, GPOs, Specialty Pharmacies, and Healthcare Services: DCI’s 2026 Update (rerun)
(1d)
The Top Pharmacy Benefit Managers of 2025: Market Share and Key Industry Developments (rerun)
(2d)
The Top 15 U.S. Pharmacies of 2025: Market Shares and Revenues at the Biggest Chains, PBMs, and Specialty Pharmacies (rerun)
(3d)
Pharmacy Copay Misuse: The Multi-Billion Dollar Issue Hiding In Plain Sight
(6d)
The 340B Contract Pharmacy Market in 2026: A Maturing Industry Dominated by Big Chains and PBMs
(1w)
Drugs, Discounts and Data: Crafting Sustainability in an Imperfect System
(2w)
Drug Channels News Roundup, May 2026: My $0.02 on Optum Rx’s Transparency, Must-Read 340B History, PBM Unbundling Update, PA Delays, and Vegas Fun
(2w)
PBM Shakeout: How Vertical Integration Is Reshaping What’s Next (VIDEO)
(3w)
Protecting Gross-to-Net Performance Through Single-Channel Ecosystems
(4w)
Drug Channels News Roundup, Mid-May 2026: Flawed Launch Price Math, Rising Pharmacy Closures, Hospital Pay Realities, 340B Hospitals vs. Grantees, and a Luxury Take on Specialty Pharmacy
(4w)
340B in 2026: Market Shifts, Policy Battles, and What They Mean for Stakeholders (NEW Live Video Webinar)
(1mo)
The Hidden Costs of Over-Customizing Your Hub Technology Stack
(1mo)
Specialty Pharmacy Accreditation: DCI’s Exclusive Analysis Reveals a Market at an Inflection Point
(1mo)
Where Gross-to-net Pressure Actually Lives After Launch
(1mo)
Drug Channels News Roundup, April 2026: PBM Specialty Pharmacy Steering, MLR Profit Shifting, Hospitals’ Fake Prices, and a Peek Behind the Scenes at DCI
(1mo)
Beyond Formulary Access: Building a Scalable Pharmaceutical Manufacturer Commercial Platform for Direct-to-Consumer and Employer Channels
(1mo)
Minnesota’s 340B Hospitals Make One Billion More From 340B Than They Spend on Uncompensated Care
(1mo)
The Top 15 Specialty Pharmacies of 2025: PBM-Affiliated Pharmacies Dominate While Health Systems and Independents Gain Ground
(1mo)
The Omnichannel Gap: Building the CRM of the Future for Patient Services
(1mo)
European Biotechnology Magazine
Novartis and Orionis get stuck in with new “molecular glue” R&D deal worth up to $1.4bn
(8h)
Heidelberg-based Veraxa ventures onto Nasdaq in turbulent market environment
(12h)
Scenic Biotech joins Michael J. Fox LRRK2 consortium with a novel lysosomal bet on Parkinson’s
(13h)
Sanofi’s $11.6bn Bioverativ purchase looks hit-and miss after phase 3 rare diseases drug runs into trouble
(1d)
Circio completes NOK300m financing to fund circular RNA platform development
(1d)
AlzeCure shares soar over 300% after Eli Lilly strikes Alzheimer’s deal worth over $1bn
(1d)
Boehringer/Zealand obesity drug delivers Phase III weight loss, but side effects raise questions
(2d)
Bial drops pariceract after Phase IIb failure in GBA-associated Parkinson’s
(2d)
GSK taps Engitix’s platform in liver fibrosis deal worth up to £44.5m upfront
(3d)
Next-gen oligonucleotides to transform patient care
(3d)
Roche bets on BTK degradation in $2.3bn Nurix deal
(3d)
ADC Therapeutics stock halves after Zynlonta Phase III records three times more deaths than control arm
(6d)
Biotechnology expert joins CDMO
(6d)
Lilly and Boehringer pause $2bn German investments over planned drug-spending curbs
(6d)
Ona Therapeutics bags $86.6m Series B for stealth ADC push
(1w)
Ingenix raises €13m to scale AI drug development engine
(1w)
3PBIOVIAN expands its mammalian capacity with an additional 2,000 L bioreactor
(1w)
IMU Biosciences secures US$53m to decode the immune system
(1w)
Abivax delivers Phase 3 ulcerative colitis win, but safety concerns trigger market sell-off
(1w)
A fresh start for Molecular Health: technology core becomes start-up Lucera
(1w)
Drug Hunter
Locking the Sec61 Gate to Corral Disease
(5h)
linerixibat
(1d)
NVP-INE963
(2d)
sonrotoclax (BGB-11417)
(3d)
Module 4 Quiz
(3d)
Brushstrokes of Biology: Cell Painting for Mechanism of Action
(6d)
tazemetostat
(1w)
acoziborole
(1w)
milsaperidone
(1w)
PF-06826647
(1w)
April 2026 Patent Gazette
(2w)
Academic-Industrial Collaboration Leads to Radical Method for Expanding CRBN-Engager SAR
(2w)
Amino Acids Cheat Sheet
(2w)
paclitaxel
(2w)
Revisiting Mitochondrial Uncoupling for Metabolic Disease
(2w)
April 2026
(2w)
TNG961
(3w)
Degrader–Antibody Conjugates: Can Targeted Delivery Improve Tolerability?
(3w)
ASTX295
(3w)
NVP-ECI830
(3w)
Labiotech.EU
How Daiichi Sankyo aims to become a top five oncology player by 2035
(1d)
Beyond amyloid and dopamine: emerging technologies reshaping neurology
(1d)
Pharma in Spain: why global investors and innovators are moving in
(2d)
Top biotech deals in May 2026
(3d)
Eight oncology deals in 2026 spotlight where industry leaders are betting big
(6d)
Eight oncology deals in 2026 spotlight where industry leaders are betting big
(6d)
Episode 200 Special: Joachim Eeckhout on building Labiotech and the future of biotech media
(6d)
Highlights of ASCO 2026: how is cancer care evolving?
(1w)
Surge in M&As driven by patent expirations
(1w)
The biggest biotech funding rounds in May 2026
(1w)
What China’s new CGT rules mean for biotech business
(1w)
Can WEE1 inhibitors finally make replication stress druggable?
(2w)
World MS Day Special: Immunic reveals new hope for progressive MS
(2w)
Lab Thread: integrating workflows to replace fragmented systems
(2w)
Are we ready for the next wave of proximity degraders?
(2w)
The future of organ transplants: Xenotransplantation, 3D bioprinting and stem cells
(2w)
Blockbuster sales, lawsuits, and approvals: is there a recovery in sight for Bayer in 2026?
(2w)
LSX Nordic Congress 2026: what came out of the biotech partnering event
(3w)
The problem at the heart of drug discovery: Lexogen & Ochre Bio on the power of AI on human data
(3w)
Treating pattern hair loss: how close are we?
(3w)
Bio IT World
Navigating the Perilous Journey from Lab to Market
(1d)
As AI Reshapes Drug Discovery the Lab Remains the Bottleneck
(2d)
Federation Plus Fine Tuning: The Push for Federated Learning Models Continues
(1w)
Trends from the Trenches: AI-Ready Life Sciences Data
(1w)
A ‘Credit-Score-Like’ Risk Assessment System for Investigative Drugs
(1w)
Immunai, AstraZeneca Expand Partnership, Rancho Biosciences Releases Multi-omics Datasets, Dotmatics AI Co-Scientist
(2w)
Insilico Medicine, Human Longevity Partner for Longevity Foundation Model
(2w)
Bio-IT World VIP Conference: Exploring Breadth vs. Depth
(2w)
Follow the Money: AI Drug Design Engine, Treating Multiple Myeloma, Quantum Healthcare Platform
(2w)
At Bio-IT World's 25th Anniversary, Rare Disease Takes Center Stage
(3w)
Best New Products at Bio-IT World From BioTeam, Dantech, Rancho
(3w)
Microchimerism: Lifelong Biological Connections Impacting Everyone
(3w)
From Data Chaos to Discovery: Building the Data Foundation for AI-Ready Scientific Research
(4w)
36 New Products at Bio-IT World 2026
(4w)
AI Framework for Differentiating Neurodegenerative Diseases
(1mo)
Trends from the Trenches: The Capability Jump of AI and Its Impact
(1mo)
Bacteria: Unsung Players in the Tumor Microbiome
(1mo)
Much Progress Needed Planning Research to Consider Sex as a Biological Variable
(1mo)
Craig Venter, Genomics Pioneer and Visionary, Dies
(1mo)
Follow the Money: Autoimmune, Inflammatory Disease Therapies, Antibody-Drug Conjugates, AKT1-Selective Inhibitor Programs
(1mo)
GEN News
Potential Cocaine Addiction Targets Identified Through Genetic Mapping in Rats
(2h)
New mRNA Delivery Platform Restores Muscle Function in DMD Models
(3h)
Fighting Antimicrobial Resistance with Biomaterials and Phages
(5h)
GSK to Acquire Nuvalent for $10.6B, Boosting Cancer Pipeline with Precision NSCLC Treatments
(1d)
Origins of First Eukaryotes Linked to Contributions from Multiple Bacteria and Giant Viruses
(1d)
Brain Aneurysm Study Identifies Structural, Immune Markers of Rupture Risk
(1d)
Symeres Expands Spray Drying Capabilities at Its U.S. New Jersey Site
(1d)
In Silico Devices May Improve Drug Manufacturability
(1d)
Gorilla Adenovirus Brings Natural Edge to Cancer Therapy
(1d)
Updated Amplification Tool Rapidly Detects Mycoplasma
(1d)
Innovative Tech Testing in Response to GMP Revisions
(1d)
mRNA Tails Play Key Role in Folding Regulatory Proteins
(1d)
10x Genomics Acquires Proteintech Genomics, Expanding Proteomics Capablities
(1d)
The State of Biologics Testing 2026
(1d)
T-Cell Synapse Formation Is Restrained by PTPN22–PSTPIP1 Signaling
(1d)
First-in-Human Trial Reports Promising Dual Lassa–Rabies Vaccine Data
(2d)
Incyte to Acquire Vega Therapeutics for Up-to-$2B, Growing Hematology Pipeline with Phase III VWD Candidate
(2d)
Fifteenth In Vivo Lentiviral Vector-Based Therapeutic Technology Added to VIVEbiotech’s CGT Platform
(2d)
Complete Connectome of Fruit Fly Central Nervous System Now Open-Source
(2d)
Defective HIV RNA Linked to Persistent Viremia During Long-Term ART
(2d)
Cure Today
Treating Metastatic TNBC: Dr. Hope Rugo on ADCs and Personalized Therapy
(2mo)
Understanding High-Risk Essential Thrombocythemia
(2mo)
Son’s Decision to Donate Gave His Father a Second Chance
(2mo)
Functional Precision Medicine Advances Brain Tumor Care
(2mo)
Home-Based Chemotherapy at Mayo Clinic Shows Safe Option for Patients With Cancer
(2mo)
Choosing Motherhood Amidst Stage 4 Breast Cancer
(2mo)
FDA Approves Opdivo Combo for Newly Diagnosed Advanced Hodgkin Lymphoma
(2mo)
How Honest Conversations Strengthened a Couple After Cancer
(2mo)
Cardiac Health in Cancer Survivors: A Growing Need
(2mo)
Why Open Communication is Crucial for Patients With Multiple Myeloma
(2mo)
Understanding Mental Health Referrals in Cancer Care
(2mo)
Breast Cancer Early Detection: A Bold and Breastless Survival Story
(2mo)
Talzenna Plus Xtandi Delays Prostate Cancer Progression
(2mo)
Evolving Treatment Strategies Are Reshaping mCRPC Care
(2mo)
Pimicotinib Shows Early, Strong Tumor Response in Tenosynovial Giant Cell Tumors
(2mo)
Life After Liver Cancer: A Couple’s Journey of Recovery and Care
(2mo)
Why This Breast Cancer Survivor Chose "Flatness" After Implants
(2mo)
NCCN Guidelines Expand Options for Certain Bladder Cancer Patients
(2mo)
FOURLIGHT-1 Study Data Support Atirmociclib for HR+/HER2- Breast Cancer
(2mo)
Key Updates in Bladder, Kidney and Prostate Cancer from Experts
(2mo)
Contract Pharma
Viking Therapeutics Taps Hubert Chen as Chief Medical Officer
(1h)
Harbour BioMed Adds Luisa Salter-Cid as Scientific Advisor
(1h)
PharmaEssentia Acquires Forus Therapeutics, Expanding Footprint in Canada
(2h)
Chiesi Group Acquires KalVista Pharmaceuticals for $1.9B
(6h)
ACG Packaging Materials Achieves ISO Certification for Croatia Facility
(6h)
Cytovance Biologics Adds Cell Line Development Services
(7h)
Verge Labs, Tenacia Biotech Unite to Advance CNS Pipeline
(1d)
Axplora to Consolidate UDCA Manufacturing at Vizag, India Site by End of 2026
(1d)
Genesis and Alnylam Expand Partnership to Commercialize RNAi Therapeutics for Nordic Region
(1d)
Symeres Expands Spray Drying Capabilities in Cranbury, NJ
(1d)
FibroFind Names New CEO, Adds Three Senior Hires
(1d)
FDA Approves EBGLYSS 8-Week Dosing
(1d)
Orionis Biosciences, Novartis Partner to Advance Molecular Glue Drugs
(1d)
Injectable Drug Sterilization: Key Challenges and Strategies
(1d)
Bridging the Gap: The LNP Alliance on Translating Nucleic Acid Therapeutics from Lab to Clinic
(2d)
CatalYm Announces New Chief Financial Officer Peter Garcia
(2d)
The Future of Biotech Outsourcing
(2d)
Syntax Bio Pairs With Mayo Clinic on Stem-Cell Pancreatic Cell Therapies for Type 1 Diabetes
(2d)
Syntis Bio Taps Matthew Dallas as CFO
(2d)
GSK Agrees to Acquire Nuvalent for $10.6B
(2d)
Pharma Times
NICE backs daratumumab quadruplet for newly diagnosed transplant‑ineligible myeloma
(11h)
Anocca doses first patients with precision TCR‑T therapy
(11h)
Connecta launches phase 2a trial of neuroplasticity modulator
(1d)
Aquipta recommended by NICE for acute migraine treatment
(1d)
Talvey accepted for use in Scotland for relapsed and refractory multiple myeloma
(2d)
Alzecure enters collaboration and with Lilly for Alzheimer’s project
(2d)
Survodutide trial data show targeted visceral and liver fat reductions
(3d)
Johnson & Johnson reports phase 2 data showing nipocalimab reduced SLE disease activity
(1w)
European approval enables measles protection with CSL’s immunoglobulin Privigen
(1w)
JJP Biologics reports positive interim phase 1b data for nebaprubart
(1w)
Immunotherapy boost can spare more bladder cancer patients major surgery
(1w)
Deep Science Ventures and MDC partner to accelerate brain treatments
(1w)
Aragen to manufacture Renaissance Pharma’s FDA Fast Track mAb
(1w)
Pierre Fabre Laboratories secures CHMP backing for first‑line BRAFTOVI regimen
(2w)
Resolution Therapeutics hails positive 4‑year MATCH data in liver cirrhosis
(2w)
KOALA trial opens to enrol patients for first‑in‑human KMCAR T‑cell therapy
(3w)
Pepaxti study supports use in wider myeloma population
(3w)
UCB reports positive outcomes for bimekizumab in psoriatic arthritis
(3w)
AstraZeneca wins US approval for first‑in‑class Baxfendy in hypertension
(3w)
Cellbxhealth partners with AdventHealth on CTC‑based monitoring in two major cancer studies
(3w)
Medcity News
Novartis RNA Med From $12B Deal Keeps Building Case to Become First Therapy for Rare Muscle Disease
(2h)
From Copilots to Clinical Judgment: The Next Phase of AI in Digital Behavioral Health
(6h)
AI Is Scaling Healthcare Costs Because the System Was Built That Way
(7h)
What Healthcare Leaders Get Wrong About EHR Switching
(7h)
The Identity Gap Undermining Value-Based Care
(9h)
DiMe Launches New Initiative for Virtual-First Care
(20h)
‘2030 Scares Me to Death’: Credit Analysts’ Urgent Warning for Healthcare CFOs
(1d)
Parabilis Medicines’ Quest to Drug the Undruggable Picks Up $745M From Upsized IPO
(1d)
Restoring the Patient-Clinician Relationship to the Center of Care
(1d)
From Detection to Defense: Building Fraud-Resilient Healthcare Payment Systems
(1d)
The Healthcare Payments Industry Has a Perception Problem
(1d)
Healthcare IT Isn’t Broken — But How We Design It Might Be
(1d)
Take Part in Our Survey on Healthcare AI and Security
(1d)
The 5 Areas Where Dr. Oz Says CMS Can Make Healthcare More Affordable
(1d)
GSK Gets a Pair of Near-Commercial Lung Cancer Drugs via $10.6B Nuvalent Acquisition
(2d)
Healthcare’s Assurance Infrastructure Is Broken. The Compliance Industry Built It That Way
(2d)
Bridging Movement and Machine Learning: How Clinicians Can Harness AI in Practice
(2d)
GLP-1s Are a $70 Billion Market — So Why Are Patients Still Getting Medical Advice From TikTok Influencers?
(2d)
HHS Affordability Czar Says Healthcare Costs Stem From Incentives, Not Coverage
(2d)
Incyte’s $1.25B Buyout Brings What Could Become the Next Big Bleeding Disorder Drug
(3d)
Chemical & Engineering News
Toxic chemicals accumulate in vapes as their juice runs low
(2h)
A new, ultrabright laser powers a cryo-EM advance 15 years in the making
(2h)
Coenzyme works as a molecular brake for labor
(2h)
Freepoint Eco-Systems shuts down controversial plastics pyrolysis plant
(3h)
Evonik plans revamp to make R&D go faster
(4h)
Meet Jasmine Clark, the self-described ‘mad scientist’ running for the US House
(4h)
Consortium takes on challenges of advancing sustainable materials use commercially
(8h)
Barry Snider receives 2026 Paul G. Gassman Distinguished Service Award
(1d)
Google DeepMind and Sanger Institute form AI genomics consortium
(1d)
Twistronics founders win 2026 Kavli Prize in Nanoscience
(1d)
What generational and Indigenous thinking can bring to green chemistry
(1d)
How biochemistry fuels World Cup athletes
(1d)
Crownlands emerges from stealth with a transcriptomic atlas from nasal swabs
(1d)
Pentagon ruling hits China’s WuXi AppTec
(1d)
Pentagon ruling hits China’s WuXi AppTec
(1d)
US gets a new sunscreen molecule, bemotrizinol
(1d)
Base editing in human embryos fixes some mutations and creates others
(2d)
GSK to buy cancer drug developer Nuvalent for $10.6 billion
(2d)
Australia’s $1.4 billion PFAS lawsuit could be a global model
(2d)
Bleach and an iron catalyst make epoxidation scalable and safer
(2d)
The Pharma Letter
City Therapeutics
(2h)
Wegovy pill becomes first and only daily GLP-1 weight loss tablet approved in UK
(5h)
Takeda’s zasocitinib outperforms deucravacitinib in PsO
(5h)
From raising awareness to developing treatments, Alexion is fighting HPP battle on many fronts
(5h)
Richter and Hetero collaborate on Ozempic generic
(6h)
Oriva appoints Agnès Arbat as CEO as endometriosis drug enters clinic
(8h)
Grifols breaks ground on new manufacturing site in Spain
(8h)
FDA accepts Roche’s Tecentriq sBLA for priority review
(9h)
Beren lines up $300 million ahead of potential adrabetadex launch
(9h)
Glenmark launches Winlevi in Europe
(9h)
China poised to see launch first stand-alone opioid-induced constipation treatment
(10h)
Reig Jofre launches dalbavancin in European hospital push
(10h)
Why pharma’s CDMO boom is becoming more uneven
(10h)
Pfizer weighs German investment as peers push back on reform
(11h)
Pharma trade bodies press G7 leaders on innovation agenda
(11h)
Harrow re-launches Verkazia to improve access for VKC treatment
(12h)
PhoreMost updates on oncology program and appoints CMO
(1d)
Orionis inks molecular glue collaboration with Novartis
(1d)
Ethyreal Bio launches with $101 million for thyroid disease antibody
(1d)
SonoThera closes $125 million Series B financing
(1d)
Targeted Oncology
Ozekibart Plus Chemo Shows Promising Activity in R/R Ewing Sarcoma
(2mo)
Reduced CRS Rates Support Wider Adoption of Bispecifics in Myeloma
(2mo)
GLSI-100 Vaccine Shows <1% Annual Recurrence Rate in Phase 3 Breast Cancer Trial
(2mo)
Treating Triple Negative Breast Cancer in the Frontline Setting
(2mo)
Early Phase Evaluation of Intravesical Erdafitinib in NMIBC
(2mo)
Zovegalisib Plus Fulvestrant Shows Durable PFS in PI3Kα-Mutated HR+/HER2− Metastatic Breast Cancer
(2mo)
Phase 3 Trial of Eftilagimod Alfa in First-Line NSCLC Halted After Futility Analysis
(2mo)
Keeping Bone Health Top of Mind in Androgen Deprivation Therapy
(2mo)
Introducing CELMoDs into the Multiple Myeloma Treatment Paradigm
(2mo)
Role of Dual Maintenance Remains Uncertain in Multiple Myeloma
(2mo)
PSMA PET Applications in Prostate Cancer Management
(2mo)
FDA Confirms Potential Accelerated Path for Givastomig in GE Cancer
(2mo)
Deescalation vs Intensification: How to Ensure Patients Get the Treatment They Need
(2mo)
Deescalation Therapies in Breast Cancer Treatment
(2mo)
Prospective Data Support i31-SLNB Test to Guide Biopsy Use in Melanoma
(2mo)
LITESPARK-011 Signals Shifting Paradigm in RCC
(2mo)
Biomarkers, Oncolytic Viruses, and the Promise of Personalized Treatment for Glioblastoma
(2mo)
Priority Voucher Leads to Rapid Approval of Teclistamab in Myeloma
(2mo)
How ctDNA Testing is Changing Lymphoma Treatment
(3mo)
Symptom Burden, Functional Status, and Ongoing Challenges in Progressive Small Bowel Neuroendocrine Tumor
(3mo)
MedWatch
US employers are considering dropping coverage for GLP-1 medications in 2027
(8h)
EU court urged to prioritize vaccine contract transparency over corporate interests
(9h)
EU’s new medicines act strikes a difficult balance
(9h)
Pfizer to adjust planned investments in Germany after new pricing policy
(10h)
Johnson & Johnson acquires Firefly Bio for USD 1 billion
(12h)
Teva buys Emalex Biosciences, gains late-stage drug access
(12h)
Amgen secures extension of Norwegian agreement after withdrawal from Danish market
(13h)
Eli Lilly takes weight-loss pill ad to the NBA Finals
(13h)
Analysts see prospects for upward revision at Demant after strong 2026 start
(1d)
Novo-owned weight-loss company appoints biotech executive as chairman following management shake-up
(1d)
Novo Holdings invests in US rapid-response platform
(1d)
UBS highlights several factors that could boost healthcare stocks
(1d)
Sanofi ends phase 3 trial of drug candidate for neurological disorder
(1d)
Demant reaps rewards of a popular relaunch among US veterans
(1d)
Cancer-focused Parabilis Medicines completes biotech industry's largest IPO
(1d)
Foreign investors sell Novo Nordisk shares worth more than USD 15bn
(1d)
US Novo Nordisk factory faces new FDA criticism after discovery of hair and water leaks
(1d)
BioPorto expands kidney trial following feedback from the FDA
(2d)
New AstraZeneca drugs face delay in Europe, warns CEO
(2d)
Bavarian Nordic receives smallpox vaccine order worth more than USD 100m
(2d)
In The Pipeline
Hydroxyl Radicals In Water Droplets? Doesn't Look Like It.
(1h)
A New Antibiotic Idea From An Old Source
(1d)
Insights Into Idiopathic Pulmonary Fibrosis
(2d)
Unusual Toxicity With a Protein Degrader Molecule
(3d)
The Causes of Long Covid
(7d)
Action! Action Now.
(1w)
The Current Crisis: What's Happening to Science in America
(2w)
Evaluating "Co-Scientist", a New AI Science System
(2w)
That Methyl Methacrylate Tank
(2w)
Reading the Labels on Mutant Mice
(3w)
CYA
(3w)
Stemming the AI Preprint Flood
(4w)
A Futuristic Synthesis Indeed
(4w)
What Success Can Look Like, Darn It
(4w)
More Vague, But More Useful
(4w)
Those Pesky Post Translational Modifications
(1mo)
The Latest News in Vaccine Obstruction
(1mo)
Ubiquitin Rides Again
(1mo)
Helium and the Strait of Hormuz
(1mo)
An Open Letter to Jay Bhattacharya
(1mo)
Pharmaphorum
UK approves Novo Nordisk's Wegovy pill
(3h)
Takeda's TYK2 drug bests BMS's Sotyktu in psoriasis contest
(4h)
J&J adds rare disease wAIHA to Imaavy's potential uses
(7h)
Novartis gets win for another Avidity muscular dystrophy AOC
(8h)
Basketball great Shaq fronts Lilly sleep apnoea campaign
(9h)
Anthropic puts life sciences at heart of new AI model
(10h)
SonoThera's $125m Series B heads recent biofinancings
(12h)
Lilly wins new FDA approval for eczema drug Ebglyss
(1d)
Bayer's asundexian starts EU review for ischaemic stroke
(1d)
AbbVie's migraine drug cleared for migraine attacks on NHS
(1d)
Cancer biotech Parabilis books record IPO, raising $670m
(1d)
Sanofi abandons phase 3 trial of neurology drug riliprubart
(1d)
Moderna jab on trial for cancer-causing syndrome
(2d)
Jen Norton appointed market access leader at EVERSANA
(2d)
Most doctors in UK think AI training is inadequate
(2d)
ADA: AZ reveals oral GLP-1 data in obesity, diabetes
(2d)
GSK pursues $10.6bn takeover of cancer biotech Nuvalent
(2d)
J&J lights up $1bn offer for pan-KRAS developer Firefly
(3d)
Incyte gobbles up Star's Vega haematology unit in $2bn deal
(3d)
ADA: Lilly's weight-loss reveal, and wannabes display wares
(3d)
Drug Discovery Weekly
DaltonTx launches AI drug discovery platform
(6h)
Webinar – The orchestrated lab: Moving beyond siloed automation
(10h)
Bead BioPharma emerges from stealth with novel drug platform
(10h)
AMR Bio confirms contribution to US National Action Plan
(11h)
Webinar: Overcome critical bottlenecks in fragment-based drug discovery
(12h)
GLP-1 reduces liver fat by 63%, trial results show
(1d)
From undruggable to inevitable
(1d)
NICE recommends quadruplet regimen for multiple myeloma
(1d)
UK cancer patients to benefit from genetic testing rollout
(1d)
Webinar: Modernise and scale your antibody discovery programmes
(1d)
Crystalys doses first patients in Phase II gout trial
(2d)
Over £37m funding to boost early career researchers in the UK
(2d)
Verdiva Bio presents preclinical data on obesity treatments
(2d)
UK should offer US-style incentives in rare diseases, says biotech
(2d)
New research suggests anti-IL-1β drugs could prevent lung cancer
(2d)
Webinar: How can a single, comprehensive test can enable broader viral detection?
(2d)
IMU Biosciences raises $53m to expand disease platform
(3d)
Bipolar treatment leads to rapid antidepressant effects
(3d)
The orchestrated lab: Moving beyond siloed automation
(3d)
Cracking sensitivity and resistance to Pan-RAS(ON) inhibition with KRAS
(3d)
HIT Consultant
Why Validation is Becoming the Proving Ground for AI in Life Sciences
(5h)
Med-Metrix Acquires CanAide to Automate Patient Access
(6h)
Surgical AI Startup Uncovr Emerges from Stealth with $7M Seed Funding
(8h)
Scispot Secures $8M to Expand AI-Native Operating Layer for Modern Labs
(2d)
Hybrid Care 2.0: How AI-Powered Telehealth and Predictive Analytics Are Redefining Medicine
(2d)
Blue Cross MA Inks Its First Oncology Value-Based Deal with Thyme Care
(2d)
Stepful Secures $55M to Expand AI-Powered Healthcare Workforce Training
(2d)
AGS Health Launches InnovationWorks™ Center of Excellence to Scale Revenue Cycle AI
(2d)
Tegria Appoints Former TriZetto CEO Craig Mengert to Succeed Retiring Brian Cahill
(2d)
Klinic Inc. Secures $24M to Scale Specialty Care Enablement Platform
(2d)
No Surprises Act Reform: What the Latest IDR Changes Mean for Laboratories and Diagnostic Providers
(2d)
Xealth Appoints Travis Moore as Chief Revenue Officer to Drive EHR-Integrated Digital Health Expansion
(3d)
The Alert Fatigue and EHR Friction Killing Digital Health Apps
(3d)
Leveraging Real-World Data for Proactive Protocol Design
(6d)
Alternative Funding Programs vs. In-Benefit Optimization: Designing a Sustainable Specialty Drug Strategy
(6d)
Health Catalyst to Divest Vitalware Unit for $147M to Med-Metrix
(1w)
Philips and WellSpan Health Launch 7-Year Strategic AI and Imaging Partnership
(1w)
Vida Health Partners with Instacart to Launch Category-Specific Grocery Stipends for Cardiometabolic Care
(1w)
Don’t Let Legacy Data Derail Your Health System’s Growth
(1w)
Ilant Health Secures $15M to Expand Value-Based Precision Obesity Management
(1w)
Insights: Pink Sheet
Nearly 29% Of US FDA Probationary Staff Lost In 2025 Purge, GAO Says
(21m)
UK’s HRA Maps Path To Regulatory Clarity For AI-Enabled Trials
(5h)
US-Approved Drugs Otarmeni, Idvynso And Unloxcyt Filed In EU
(7h)
Asundexian, Venglustat And Japanese Encephalitis Vaccine Among Latest EU Filings
(7h)
Japan Grapples With Off-Label Mounjaro Trade For Weight Loss
(13h)
Policy Priorities For An Innovative Korean Ecosystem
(17h)
BIOSECURE Legal Lifeline Available For Pharma Companies Using WuXi AppTec … For Now
(23h)
BsUFA IV: US FDA Willing To Select Products For Exclusivity Determinations Each Year
(1d)
Riddle Of The Sphinx: Reading Into US FDA’s Striking Silence At NPV Hearing
(1d)
Industry Urges EU To Broaden SPC Scope Under Biotech Act
(1d)
Alexion: EU JCAs Could Be A ‘Drag On Competitiveness’ Without Orphan Drug Flexibility
(1d)
UK MHRA Urges Human Oversight As AI-Generated Inspection Responses Cite Fake Regulations
(1d)
EU JCA: Milestone Report Shows Room For Improvement For Orphan Drugs And PICOs
(1d)
Pentagon Chinese Company Designations Resurface Pharma Supply Chain Concerns
(2d)
US FDA Regulatory Incentives Drive Boom In Rare Disease Applications
(2d)
Timeline Clarity, Patient Voice Integration Needed For US FDA’s National Priority Voucher Program
(2d)
Iran War: Adapt Pricing To Mitigate Rocketing Costs, Demands French Drug Industry
(2d)
Growing Use of External Controls Prompts EMA Push for Clarity
(2d)
Vertanical’s Cannabis Extract Exilby Could Break US FDA Regulatory Barriers For Botanical Products
(2d)
MFN Deals Post-Trump: Launch Price Parity Would Be Hardest To Undo
(3d)
BioXconomy
New study reveals $35 as tipping point for prescription abandonment
(2h)
Japan urged to regulate generative AI in clinical trials
(3h)
Dodging the cytokine storm: Delivering ASOs without adverse effects
(6h)
Lilly adds to neuroscience portfolio with $1bn AlzeCure Alzheimer's pact
(7h)
Sofinnova and AWS deliver AI to portfolio companies’ door
(8h)
African and European regulators prepare trials for Bundibugyo Ebola vaccines, treatments in DRC
(1d)
Legal roundup: DOJ speeds up fraud probes, more
(1d)
Parabilis Medicines sets $20 share price in $670m IPO
(1d)
J&J sets DACs on fire with $1bn acquisition of Firefly Bio
(1d)
From study design to investor confidence: De-risking early-stage biotech
(2d)
Pharma companies name new chief legal officers
(2d)
Emerging pharma: Steps to 3PL partnership success
(2d)
GSK bets $10.6bn on lung cancer future with Nuvalent buy
(2d)
Eyes on Asia: Olix, Agios, Eli Lilly
(2d)
Five essentials for pharma product launch success
(3d)
Incyte snaps up Vega Therapeutics in $2bn hematology play
(3d)
The cluster advantage: It’s not an investor requirement, but it makes a difference
(3d)
Digital twins reshaping drug trials from design to training, says analysis
(3d)
Covered entities defend 340B data integrity efforts
(3d)
Lonza and Stipple Bio strike licensing deal for precision oncology ADCs
(3d)
BioCentury
Pinnacle: Designing oral peptides to close the gap with injectable biologics
(21h)
Moving faster at the academia-industry interface — a BioCentury podcast
(21h)
LRRK2 inhibitor failure pushes Parkinson’s field toward genetic enrichment
(22h)
Where Parabilis’ massive IPO ranks among biotech debuts on NASDAQ
(22h)
The race for a vaccine against rare Ebola virus
(1d)
MHRA proposes pairing trial authorization with market access for very rare diseases
(1d)
In third deal under Miels, GSK adds targeted cancer therapies via $10.6B Nuvalent buy
(1d)
Impact of Biosecure starting to come into focus
(1d)
Calmer waters for FDA; Servier, Lilly deals — a BioCentury podcast
(2d)
Sizing up Lilly’s dealmaking spree
(2d)
Tango’s PRMT5 inhibitor adds to daraxonrasib activity in pancreatic cancer
(3d)
J&J/Firefly, Roche/Nurix each strike degrader deals: Deals Report
(3d)
In its largest M&A deal, Incyte adds late-stage bleeding candidate via Vega buy
(3d)
May’s approvals bring FDA to 20 NMEs on the year
(5d)
Ona’s $86.6M venture round among Spain’s biggest for a biotech: Finance Report
(5d)
ADCs headline first-in-human development at ASCO
(5d)
Forbion welcomes McDonald from Novo, promotes two partners
(5d)
Fred Hutch’s Sylvain Simon named ‘Rising Star’ at Grand Rounds U.S. in Seattle
(6d)
Meeting sign of acting FDA leadership trying to right the ship
(6d)
Congressional concern growing over integration of Chinese, U.S. biopharma
(6d)
SCRIP
J&J’s Imaavy Goes Two-For-Two With Pivotal Trial Success In wAIHA
(32m)
Takeda’s Zasocitinib Beats BMS’s Sotyktu In Moderate-To-Severe Plaque Psoriasis
(42m)
ADA 2026: Roche Still Looking For Ways To Stand Out In Obesity
(4h)
Executives On The Move: Four CEOs And Five CFOs Among This Week’s Changes
(6h)
US Drug Shortages Ease But Discontinuations Surge, Asia Supply Chain Risks Run Deep
(7h)
Positive Del-Brax Biomarker Data Offers Early Support For Novartis’s Avidity Bet
(7h)
Orionis Back In Novartis’s Orbit With New Molecular Glue Deal
(7h)
Ambitious Oriva Wants To Be Key Player In Women’s Health
(12h)
Parabilis Breaks Kailera’s Short-Lived Biopharma IPO Record
(23h)
SonoThera Raises $125m To Advance Next-Gen DMD Gene Therapy
(23h)
J&J Opts Not To Follow The Oncology Crowd
(23h)
ADA 2026: AstraZeneca To Move Fast On Obesity And Heart Pill Combinations
(1d)
Insights from industry leaders on China’s rise as a global powerhouse in drug innovation
(1d)
Opportunities and best practices in early phase research
(1d)
Sanofi Stops Phase III MOBILIZE Study As It Reviews Riliprubart’s CIDP Program
(1d)
Improved access, broader participation, and faster enrollment through community-based trials
(1d)
WuXi AppTec, Novogene Added To Pentagon List Of ‘Chinese Military Companies’
(1d)
Bial Ends Development Of Parkinson’s Disease Drug After Phase IIb Fail
(2d)
UBS: Lilly Still Set To Lead Obesity Market, Despite Novo Gains With Wegovy Pill
(2d)
ASCO: Novartis To Face Challenges In Growing Radiopharmaceutical Space
(2d)